Table 1.
Demographics and hospitalization data in COVID-19 and control groups.
| Demographic n = 2292 | Group 1 | Group 2 | Group 3 | Group 4 |
|---|---|---|---|---|
| PCR/Symptom Status | COVID-19 + ve/Sx + ve | COVID-19 − ve/Sx+ | COVID-19 − ve/Sx − ve | PCR/Sx Unknown |
| Number (percent) | 28 (1.2) | 36 (2) | 90 (3.9) | 2129 (92.9) ^ |
| Entry/testing (Age ± SD) | 54 ± 11/72 ± 9.7 years | 54 ± 8/73 ± 8.6 years | 54 ± 8.6/73 ± 9.0 years | 61 ± 12.4 */NA years |
| Sex (%male = m) NSS |
m = 22 female = 5 (81.5) |
m = 36 female = 9 (80) |
m = 72 female = 13 (84.7) |
m = 1684 female = 209 (89) |
| Ethnicity (%AA):White | 17 (63):10 (37) | 33 (73):12 (27) | 54 (60):36 (40) | 96 (51):969 (49) |
| Mortality number (%) | 5 (18.5) | 5 (10.9) | 5 (5.6) p = 0.05 vs. 1 | NA |
| COVID-19 test (%) | 22 (82%) known | 41 (89%) known | 49 (53%) ** | NA |
| Vaccinated (%) | yes 15 (56%) no 12 (44%) |
yes 22 (54%) no 19 (46%) |
yes 40 (66%) no 21 (34%) |
NA |
Sx + ve–symptomatic; ^ p < 0.0001 group 4 vs. group 1 by ANOVA and Dunnett’s post hoc analysis; * p < 0.0001 as compared to Group 1 by t-test; NSS—not statistically significant; AA—African American; NA—not available. Diagnostic tests were SARS-CoV2Xpert Xpress assay, Cepheid GeneXpert instrument, starting 30 March 2020; Fluvid (also tests for influenza A&B later RSV), PHRL (none in Group 3), PCR outside hospital, where test was unknown, it was not included in the data.** p < 0.014 vs. Group 1, and p < 0.0001 vs. Group 2. All vaccine recipients received at least 2 doses of mRNA-1273/Moderna vaccine.